These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33839737)

  • 1. SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency.
    Li M; Lou F; Fan H
    Signal Transduct Target Ther; 2021 Apr; 6(1):151. PubMed ID: 33839737
    [No Abstract]   [Full Text] [Related]  

  • 2. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum.
    Uriu K; Kimura I; Shirakawa K; Takaori-Kondo A; Nakada TA; Kaneda A; Nakagawa S; Sato K;
    N Engl J Med; 2021 Dec; 385(25):2397-2399. PubMed ID: 34731554
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of BNT162b2- and CVnCoV-elicited sera and of convalescent sera toward SARS-CoV-2 viruses.
    Hein S; Herrlein ML; Mhedhbi I; Bender D; Haberger V; Benz N; Eisert J; Stingl J; Dreher M; Oberle D; Schulze J; Mache C; Budt M; Hildt C; Wolff T; Hildt E
    Allergy; 2022 Jul; 77(7):2080-2089. PubMed ID: 34820854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants.
    Sun H; Xu J; Zhang G; Han J; Hao M; Chen Z; Fang T; Chi X; Yu C
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients.
    Valleriani F; Mancuso E; Vincifori G; Teodori L; Di Marcantonio L; Spedicato M; Leone A; Savini G; Morelli D; Bonfini B; Lorusso A
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Covid-19 convalescent plasma and SARS-CoV-2 viral variants.
    Joob B; Wiwanitkit V
    Transfus Clin Biol; 2021 Aug; 28(3):306. PubMed ID: 34116915
    [No Abstract]   [Full Text] [Related]  

  • 9. Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19.
    Zahra FT; Bellusci L; Grubbs G; Golding H; Khurana S
    Ann Rheum Dis; 2022 Jul; 81(7):1044-1045. PubMed ID: 35144925
    [No Abstract]   [Full Text] [Related]  

  • 10. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.
    Seghatchian J
    Transfus Apher Sci; 2021 Feb; 60(1):103051. PubMed ID: 33461918
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-acute COVID-19 syndrome after reinfection and vaccine breakthrough by the SARS-CoV-2 Gamma variant in Brazil.
    Penetra SLS; da Silva MFB; Resende P; Pina-Costa A; Santos HFP; Guaraldo L; Calvet GA; Ogrzewalska M; Arantes I; Zukeram K; de Araújo MF; Lima ABM; Lopes RS; Lira-Silva LR; Moraes IV; Wakimoto MD; Fuller TL; Gabaglia CR; Espíndola OM; Bonaldo MC; Daniel-Ribeiro CT; Whitworth J; Smith C; Nielsen-Saines K; Pauvolid-Correa A; Siqueira MM; Brasil P
    Int J Infect Dis; 2022 Jan; 114():58-61. PubMed ID: 34757006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isotyping and quantitation of the humoral immune response to SARS-CoV-2.
    Goyins KA; Yu JJ; Papp SB; Beddard R; Murthy AK; Chambers JP; Arulanandam BP
    Exp Biol Med (Maywood); 2022 Jun; 247(12):1055-1060. PubMed ID: 35369776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
    Raturi M; Kusum A; Kala M; Mittal G; Sharma A; Bansal N
    Transfus Clin Biol; 2021 Aug; 28(3):300-302. PubMed ID: 33971318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma.
    Yu D; Li YF; Liang H; Wu JZ; Hu Y; Peng Y; Li TJ; Hou JF; Huang WJ; Guan LD; Han R; Xing YT; Zhang Y; Liu J; Feng L; Li CY; Liang XL; Ding YL; Zhou ZJ; Ji DM; Wang FF; Yu JH; Deng K; Xia DM; Dong DM; Hu HR; Liu YJ; Fu DX; He YL; Zhou DB; Yang HC; Jia R; Ke CW; Du T; Xie Y; Zhou R; Li CS; Wang ML; Yang XM
    Adv Sci (Weinh); 2022 May; 9(14):e2104333. PubMed ID: 35403837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three SARS-CoV-2 antibodies provide broad and synergistic neutralization against variants of concern, including Omicron.
    Wang S; Sun H; Zhang Y; Yuan L; Wang Y; Zhang T; Wang S; Zhang J; Yu H; Xiong H; Tang Z; Liu L; Huang Y; Chen X; Li T; Ying D; Liu C; Chen Z; Yuan Q; Zhang J; Cheng T; Li S; Guan Y; Zheng Q; Zheng Z; Xia N
    Cell Rep; 2022 May; 39(8):110862. PubMed ID: 35594869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Is convalescent plasma an alternative treatment for Covid-19 patients?].
    Trejo-Gómor JE; Dimas-González J; Lagunas-Martínez A
    Salud Publica Mex; 2020; 62(6):870-871. PubMed ID: 33620985
    [No Abstract]   [Full Text] [Related]  

  • 19. Vaccination of COVID-19 convalescent plasma donors increases binding and neutralizing antibodies against SARS-CoV-2 variants.
    Di Germanio C; Simmons G; Thorbrogger C; Martinelli R; Stone M; Gniadek T; Busch MP
    Transfusion; 2022 Mar; 62(3):563-569. PubMed ID: 35129839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: benefits and risks of passive immunotherapeutics.
    Gupta A; Karki R; Dandu HR; Dhama K; Bhatt ML; Saxena SK
    Hum Vaccin Immunother; 2020 Dec; 16(12):2963-2972. PubMed ID: 32962524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.